Verici Dx Launches Board Search After Non-Executive Director Resigns

Verici Dx Plc ( (GB:VRCI) ) has shared an announcement.

Verici Dx plc, a UK- and U.S.-based precision diagnostics specialist for transplant patients, develops AI-enabled, multiomic tests such as its flagship Tutivia™ assay for early detection of acute kidney transplant rejection. Operating at the intersection of laboratory and data science, the company aims to provide clinicians with rigorous, real-world validated tools to manage transplant risk more effectively.

The company announced that Non-Executive Director James McCullough has resigned from the Board with immediate effect to focus on his role as CEO of Renalytix plc. Verici Dx has begun a search for a replacement non-executive director, a move that signals ongoing board refreshment while management publicly thanked McCullough for his five years of contribution and emphasized continuity in governance during the transition.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.75 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Spark’s Take on VRCI Stock

According to Spark, TipRanks’ AI Analyst, VRCI is a Neutral.

Verici Dx Plc’s overall stock score is driven by positive corporate events and technical indicators, which are offset by financial performance challenges and valuation concerns. The company’s strategic initiatives and market expansion efforts are promising, but ongoing profitability and cash flow issues present significant risks.

To see Spark’s full report on VRCI stock, click here.

More about Verici Dx Plc

Verici Dx plc is a precision diagnostics company focused on transforming care for organ transplant patients. The company uses multiomic analysis and proprietary artificial intelligence to deliver predictive, data-driven tools that help clinicians optimize therapy, guide biopsy decisions, and stratify risk, with its lead product Tutivia™ targeting early detection of acute rejection after kidney transplants.

Average Trading Volume: 1,263,948

Technical Sentiment Signal: Sell

Current Market Cap: £7.95M

See more data about VRCI stock on TipRanks’ Stock Analysis page.